Loading...
XNASMYGN
Market cap1.35bUSD
Jan 10, Last price  
14.83USD
1D
0.34%
1Q
-38.41%
Jan 2017
-11.04%
Name

Myriad Genetics Inc

Chart & Performance

D1W1MN
XNAS:MYGN chart
P/E
—
P/S
1.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.73%
Rev. gr., 5y
-2.41%
Revenues
753m
+11.03%
82,406,000114,279,000157,126,000333,629,000326,527,000362,648,000402,084,000496,005,000613,165,000778,216,000723,100,000753,800,000771,400,000772,600,000851,100,000851,100,000557,000,000690,600,000678,400,000753,200,000
Net income
-263m
L+135.09%
-39,978,000-38,189,000-34,962,00047,845,00084,615,000152,303,000100,710,000112,151,000147,139,000176,225,00080,200,000125,300,00021,800,000131,000,0004,600,0004,600,000-223,700,000-27,200,000-112,000,000-263,300,000
CFO
-111m
L+4.33%
-23,304,000-28,027,000-25,851,000103,736,00084,042,000155,086,000130,759,000141,846,000173,866,000190,213,000140,500,000166,300,000106,200,000115,900,00083,700,00083,700,000-26,900,00018,200,000-106,300,000-110,900,000
Dividend
Jul 01, 20091.75 USD/sh
Earnings
Feb 25, 2025

Profile

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
URL
https://myriad.com/
IPO date
Oct 06, 1995
Employees
2,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
753,200
11.03%
678,400
-1.77%
Cost of revenue
897,800
802,100
Unusual Expense (Income)
NOPBT
(144,600)
(123,700)
NOPBT Margin
Operating Taxes
1,100
(28,600)
Tax Rate
NOPAT
(145,700)
(95,100)
Net income
(263,300)
135.09%
(112,000)
311.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
117,600
6,300
BB yield
-7.42%
-0.54%
Debt
Debt current
16,200
14,100
Long-term debt
249,500
275,900
Deferred revenue
Other long-term liabilities
71,500
41,300
Net debt
124,800
120,300
Cash flow
Cash from operating activities
(110,900)
(106,300)
CAPEX
(73,300)
(45,300)
Cash from investing activities
31,900
(77,500)
Cash from financing activities
152,900
(8,000)
FCF
(157,600)
(176,100)
Balance
Cash
140,900
114,900
Long term investments
54,800
Excess cash
103,240
135,780
Stockholders' equity
(632,300)
(374,300)
Invested Capital
1,639,100
1,441,600
ROIC
ROCE
EV
Common stock shares outstanding
82,800
80,600
Price
19.14
31.91%
14.51
-47.43%
Market cap
1,584,792
35.51%
1,169,506
-45.68%
EV
1,709,592
1,289,806
EBITDA
(82,700)
(71,000)
EV/EBITDA
Interest
2,900
3,200
Interest/NOPBT